Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT), Northwest Biotherapeutics ("NWBT") announced that Lonza Group AG has withdrawn all claims of patent infringement involving NWBT's DCVax(R)-Brain product and other NWBT DCVax(R) products other than DCVax(R)-Prostate. Lonza had alleged that NWBT's DCVax(R) cancer vaccine products infringed certain gene expression technology patents held by Lonza. However, as could be seen from publicly available information sources -- available before the Lonza lawsuit was filed as well as since then -- NWBT does not use any gene modification or gene expression system in its DCVax(R) products.

Lonza filed suit...

Want to see the full article?

• Purchase this article for only $3.00